Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom
Recruitment status was: Recruiting
RATIONALE: Studying samples of blood from healthy volunteers in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in healthy volunteers.
Healthy, no Evidence of Disease
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
Other: questionnaire administration
|Official Title:||A Population Based Control Collection for Genetic Studies in East Anglia|
- Acquisition of blood samples and epidemiological information
- Investigation of whether polymorphisms in putative cancer predisposition genes are associated with an increased risk of cancer
- Examination of the interactions between genetic and nongenetic risk factors
|Study Start Date:||February 2008|
- To obtain blood samples and simple epidemiological information on a population-based series of adult individuals without cancer.
- To establish whether polymorphisms in putative cancer predisposition genes are associated with an increased risk of cancer by comparing the frequency of alterations in these genes with the corresponding frequency in a comparable series of cancer patients.
- To examine the interactions between genetic and non-genetic risk factors.
OUTLINE: This is a multicenter study.
Participants complete a simple epidemiological questionnaire.
Participants undergo blood sample collection. DNA is extracted from these samples for polymorphism analysis of low penetrance cancer susceptibility genes in the following related clinical trials: MREC-SEARCH-CANCER, MREC-SEARCH-PROSTATE, and MREC-SEARCH-BREAST. They may also be used in the analyses of the following related clinical trials: MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL.
PROJECTED ACCRUAL: A total of 2,000 male and 2,000 female participants will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00757991
|University of Cambridge Cancer Research UK||Recruiting|
|Cambridge, England, United Kingdom, CB1 8RN|
|Contact: Contact Person 44-122-374-0166 email@example.com|
|Study Chair:||Paul Pharoah, MD||Cancer Research UK|